"US Scientist Controversy: Impact on China's Anti-Ageing Sector"

The resignation of Harvard scientist David Sinclair, a key figure in NAD therapy research, has cast doubts on the efficacy of anti-ageing treatments, potentially impacting China's booming NMN supplement industry. Despite Sinclair's controversial claims and financial conflicts of interest, Chinese companies like GeneHarbor have significantly reduced NMN production costs, making the supplements more accessible. However, regulatory hurdles and scientific skepticism continue to challenge the industry's growth.